OpenAI has launched a new $100 ChatGPT Pro tier with higher Codex limits, positioning it between the $20 Plus plan and $200 ...

It has been around a year since Beam Therapeutics slashed its headcount and R&D programmes to focus mainly on a sickle cell disease candidate – and the biotech has now revealed the first data with the ...

Tesla is reportedly reviving plans for a smaller, lower-cost EV built in China first, a move that could support sales and ...

From agentic AI workflows to product-led growth and GEO pipelines, here's a data-backed breakdown of 18 growth marketing ...

Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...